Oncorus to Present at the Jefferies London Healthcare Conference
On November 17, 2021, Oncorus, a leader in viral immunotherapies, announced that CEO Theodore Ashburn will present at the Jefferies London Healthcare Conference.
The presentation will be available for on-demand viewing starting on November 18, 2021, at 3:00 a.m. ET on Oncorus' website. A replay will be accessible for 30 days post-event.
Oncorus is advancing therapies like ONCR-177, ONCR-021, and ONCR-788, focusing on innovative delivery methods and significant unmet medical needs in cancer treatment.
- None.
- None.
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Jefferies London Healthcare Conference.
The presentation will be available for on-demand viewing beginning Thursday, November 18, 2021 at 3:00 a.m. ET under the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/. A replay of the presentation will be archived on Oncorus’ site for 30 days following the event.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our oncolytic Herpes Simplex Virus (HSV) Platform and Synthetic viral RNA (vRNA) Immunotherapy Platform.
Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering Synthetic vRNA Immunotherapy Platform involves a highly innovative, novel combination of RNA- and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer. Our lead IV-administered Synthetic vRNA Immunotherapy clinical candidates, ONCR-021 and ONCR-788, are both currently in IND-enabling studies.
Please visit www.oncorus.com to learn more.
Media Contact:
Liz Melone
liz@scientpr.com
Investor Contact:
Stern Investor Relations
Julie Seidel
Julie.seidel@sternir.com
FAQ
When will Oncorus present at the Jefferies London Healthcare Conference?
Where can I watch Oncorus' presentation from the Jefferies Conference?
What is the focus of Oncorus' research?
What are the lead programs of Oncorus?
How long will the presentation replay be available?
